Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Investigation

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 17823655PMCID PMC1964508
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.

  2007cited by this paper
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  2006cited by this paper
• From acute ER stress to physiological roles of the Unfolded Protein Response

  2006cited by this paper
• Peroxisome Proliferator-Activated Receptor Agonists Modulate Heart Function in Transgenic Mice with Lipotoxic Cardiomyopathy

  2005cited by this paper
• Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock.

  2005cited by this paper
• Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

  2005cited by this paper
• Cardiomyocyte-Specific Knockout and Agonist of Peroxisome Proliferator–Activated Receptor-γ Both Induce Cardiac Hypertrophy in Mice

  2005cited by this paper
• Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

  2005cited by this paper
• Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance.

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1

  2005cited by this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Functional role of RXRs and PPARgamma in mature adipocytes.

  2005cited by this paper
• Therapeutic roles of peroxisome proliferator-activated receptor agonists.

  2005cited by this paper
• Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone.

  2005cited by this paper
• Fluid retention mediated by renal PPARgamma.

  2005cited by this paper
• Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats.

  2005cited by this paper
• Apolipoprotein B Production Reduces Lipotoxic Cardiomyopathy

  2004cited by this paper
• Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity.

  2004cited by this paper
• Peroxisome proliferator-activated receptor gamma in diabetes and metabolism.

  2004cited by this paper
• Roles of CHOP/GADD153 in endoplasmic reticulum stress

  2004cited by this paper
• Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity.

  2003cited by this paper
• Impact of aging on myocardial metabolic response to dobutamine.

  2003cited by this paper
• Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass*

  2003cited by this paper
• Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy.

  2003cited by this paper
• Regulation of the human GLUT4 gene promoter: Interaction between a transcriptional activator and myocyte enhancer factor 2A

  2003cited by this paper
• Lipotoxicity: when tissues overeat

  2003cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression.

  2003cited by this paper
• Lipotoxic diseases.

  2002cited by this paper
• Disruption of Leptin Signaling Contributes to Cardiac Hypertrophy Independently of Body Weight in Mice

  2002cited by this paper
• Adaptation and maladaptation of the heart in diabetes: Part I: general concepts.

  2002cited by this paper
• Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.

  2002cited by this paper
• The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus.

  2002cited by this paper
• Mechanisms of lipoapoptosis: implications for human heart disease.

  2002cited by this paper
• Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training.

  2002cited by this paper
• Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone.

  2002cited by this paper
• A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis.

  2001cited by this paper
• Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1

  2001cited by this paper
• A novel mouse model of lipotoxic cardiomyopathy.

  2001cited by this paper
• The MEF2A Isoform Is Required for Striated Muscle-specific Expression of the Insulin-responsive GLUT4 Glucose Transporter*

  2000cited by this paper
• Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction.

  2000cited by this paper
• Lipotoxic heart disease in obese rats: implications for human obesity.

  2000cited by this paper
• Lipoprotein Lipase-mediated Selective Uptake from Low Density Lipoprotein Requires Cell Surface Proteoglycans and Is Independent of Scavenger Receptor Class B Type 1*

  2000cited by this paper
• PPAR signaling in the control of cardiac energy metabolism.

  2000cited by this paper
• Quantitative determination of ceramide using diglyceride kinase.

  2000cited by this paper
• Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes.

  1998cited by this paper
• Myocyte enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in transgenic mice. Regulation of MEF2 DNA binding activity in insulin-deficient diabetes.

  1998cited by this paper
• Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.

  1996cited by this paper
• Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy.

  1993cited by this paper
• A simple method for the isolation and purification of total lipides from animal tissues.

  1957cited by this paper

• An integrative approach to identify novel miRNA-mRNA interaction networks in LMNA-cardiomyopathy

  2026cites this paper
• Interorganelle competition for linoleic acid underlies steatotic liver pathology

  2026cites this paper
• The Ethanol Extract of Sugemule-3 Decoction Treats Isoproterenol-induced Heart Failure in Rats via PPARγ/PGC-1 Pathway

  2025influential citation
• Unraveling mitochondrial crosstalk: a new frontier in heart failure pathogenesis

  2025cites this paper
• Systems biology approaches investigating mitochondrial dysfunction in cyanotic heart disease: a systematic review

  2025cites this paper
• Aged polylactic acid microplastics exacerbate lipid metabolism disorders and cardiac dysfunction via PPARγ activation in zebrafish: A comparative study with polymers and oligomers.

  2025cites this paper
• Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?

  2025cites this paper
• The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction

  2025cites this paper
• Associations of PPARG and PPARGC1A Polymorphisms with Ritodrine-Induced Adverse Events in Patients with Preterm Labor

  2025cites this paper
• Intensity, Duration, and Context Dependency of the Responses to Nutrient Surplus and Deprivation Signaling in the Heart: Insights Into the Complexities of Cardioprotection

  2025cites this paper
• Cardiac lipid droplets differ under pathological and physiological conditions

  2025cites this paper
• Design, synthesis and anti-diabetic evaluation of novel PPAR agonists based on functional group-oriented strategy.

  2025cites this paper
• Lipotoxicity as a therapeutic target in the type 2 diabetic heart.

  2025cites this paper
• Vitamin A deficiency and male-specific effects on heart function in mice.

  2025cites this paper
• Pioglitazone mitigates high-fat diet-induced cardiac lipotoxicity and vulnerable arrhythmias by reducing excess lipid intermediates.

  2025cites this paper
• Maternal obesity negatively impacts cardiac progenitor cell survival in heart adulthood offspring.

  2025cites this paper
• Metabolic and Mitochondrial Dysregulations in Diabetic Cardiac Complications

  2025cites this paper
• The Protective Role of miR-130b-3p Against Palmitate-Induced Lipotoxicity in Cardiomyocytes Through PPARγ Pathway

  2024cites this paper
• Role of Quercetin in Diabetic Cardiomyopathy

  2024cites this paper
• Pioglitazone Alleviates β1-Adrenergic Receptor Antibody-Induced Atrial Fibrillation Susceptivity via Mitigation of PPAR-γ-Mediated Metabolic Inflexibility.

  2024cites this paper
• Mitochondrial abnormalities in septic cardiomyopathy.

  2024cites this paper
• The beneficial impact of curcumin on cardiac lipotoxicity.

  2024cites this paper
• Elucidating the interplay of PPAR gamma inhibition and energy demand in adriamycin‐induced cardiomyopathy: In Vitro and In Vivo perspective

  2024cites this paper
• PPARγ drives mitochondrial stress signaling and the loss of atrial cardiomyocytes in newborn mice exposed to hyperoxia

  2024cites this paper
• Quantitative proteomics reveals PPAR signaling pathway regulates the cardiomyocyte activity of neonatal mouse heart

  2023cites this paper
• Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease

  2023cites this paper
• Mapping the cellular and molecular landscape of cardiac non-myocytes in murine diabetic cardiomyopathy

  2023cites this paper
• Circulating sphingolipids in heart failure

  2023cites this paper
• Myocardin-related transcription factor A, regulated by serum response factor, contributes to diabetic cardiomyopathy in mice.

  2023cites this paper
• Advances in Metabolic Remodeling and Intervention Strategies in Heart Failure

  2023cites this paper
• Transcriptional regulation of adipogenin expression in liver steatosis by hepatic peroxisome proliferator‐activated receptor gamma

  2023cites this paper
• Cardiac Metabolism, Reprogramming, and Diseases

  2023cites this paper
• Cardiac lipid metabolism, mitochondrial function and heart failure.

  2023cites this paper
• Epicardial adipose tissue and cardiac lipotoxicity: A review.

  2023cites this paper
• Deciphering the decline of metabolic elasticity in aging and obesity.

  2023cites this paper
• Myocardial Metabolism in Heart Failure

  2023cites this paper
• A high-throughput drug screening identifies luteolin as a therapeutic candidate for pathological cardiac hypertrophy and heart failure

  2023cites this paper
• Integrated Control of Fatty Acid Metabolism in Heart Failure

  2023cites this paper
• Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus

  2023cites this paper
• Qiliqiangxin: A multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms?

  2023cites this paper
• Impact of Prenatal Exposure to Maternal Diabetes and High-Fat Diet on Postnatal Myocardial Ketone Body Metabolism in Rats

  2023cites this paper
• A genetic locus complements resistance to Bordetella pertussis-induced histamine sensitization

  2023cites this paper
• The TMEM43 S358L mutation affects cardiac, small intestine, and metabolic homeostasis in a knock-in mouse model.

  2023cites this paper
• Adriamycin downregulates the expression of KLF4 in cardiomyocytes in vitro and contributes to impaired cardiac energy metabolism in Adriamycin-induced cardiomyopathy

  2023cites this paper
• The dynamic interplay between cardiac mitochondrial health and myocardial structural remodeling in metabolic heart disease, aging, and heart failure

  2023cites this paper
• Nogo-A reduces ceramide de novo biosynthesis to protect from heart failure.

  2022cites this paper
• A hypothesis concerning the role of PPAR family on cardiac energetics in Adriamycin‐induced cardiomyopathy

  2022cites this paper
• PPARγ and NOTCH Regulate Regional Identity in the Murine Cardiac Outflow Tract

  2022cites this paper
• Maternal obesity: influencing the heart right from the start

  2022cites this paper
• Animal Models of Dysregulated Cardiac Metabolism

  2022cites this paper
• The Potential Role of PPARs in the Fetal Origins of Adult Disease

  2022cites this paper
• Predicting the risk of left ventricular diastolic dysfunction in obesity

  2022cites this paper
• PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery

  2022cites this paper
• Transcription Factors Involved in the Development and Prognosis of Cardiac Remodeling

  2022cites this paper
• Exploring the Pattern of Metabolic Alterations Causing Energy Imbalance via PPARα Dysregulation in Cardiac Muscle During Doxorubicin Treatment

  2022cites this paper
• The PPARγ pathway determines electrophysiological remodelling and arrhythmia risks in DSC2 arrhythmogenic cardiomyopathy

  2022cites this paper
• Molecular mechanisms of coronary microvascular endothelial dysfunction in diabetes mellitus: focus on mitochondrial quality surveillance

  2022cites this paper
• Metabolic Complications in Cardiac Aging

  2021cites this paper
• The antithetic role of ceramide and sphingosine‐1‐phosphate in cardiac dysfunction

  2021cites this paper
• Sirtuins-Mediated System-Level Regulation of Mammalian Tissues at the Interface between Metabolism and Cell Cycle: A Systematic Review

  2021cites this paper
• Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug

  2021cites this paper
• FULMINANT MYOCARDITIS-A UNIQUE COMPLICATION OF COVID-19

  2021cites this paper
• Low-dose PCB126 exposure disrupts cardiac metabolism and causes hypertrophy and fibrosis in mice.

  2021cites this paper
• Relevance of mitochondrial dysfunction in heart disease associated with insulin resistance conditions

  2021cites this paper
• Circulating exosomes in cardiovascular disease: Novel carriers of biological information.

  2021cites this paper
• Targeting fatty acid metabolism for fibrotic disorders

  2021cites this paper
• Maternal obesity causes fetal cardiac hypertrophy and alters adult offspring myocardial metabolism in mice

  2021cites this paper
• Implication of Sphingolipid Metabolism Gene Dysregulation and Cardiac Sphingosine-1-Phosphate Accumulation in Heart Failure

  2021cites this paper
• PPAR control of metabolism and cardiovascular functions

  2021cites this paper
• Ectopic Overexpression of PPARγ2 in the Heart Determines Differences in Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones in a Mouse Model of Diabetes

  2021cites this paper
• CD36 Signaling in Diabetic Cardiomyopathy

  2021cites this paper
• Differentially expressed genes, lncRNAs, and competing endogenous RNAs in Kawasaki disease

  2021cites this paper
• SIRT6 transcriptionally regulates fatty acid transport by suppressing PPARγ

  2021cites this paper
• Nuclear Receptors in Myocardial and Cerebral Ischemia—Mechanisms of Action and Therapeutic Strategies

  2021cites this paper
• Attenuation of Cardiomyopathy Induced in Sub-Chronic Exposure of Acrolein by Sulforaphane via Indirect PPARy Expression Promoter

  2021cites this paper
• High fat diet altered cardiac metabolic gene profile in Psammomys obesus gerbils

  2020cites this paper
• An Important Role for DNMT3A-Mediated DNA Methylation in Cardiomyocyte Metabolism and Contractility

  2020cites this paper
• Enhancing fatty acid oxidation negatively regulates PPARs signaling in the heart.

  2020cites this paper
• Positive Reinforcing Mechanisms between GPR120 and PPARγ Modulate Insulin Sensitivity.

  2020cites this paper
• Myocardium Metabolism in Physiological and Pathophysiological States: Implications of Epicardial Adipose Tissue and Potential Therapeutic Targets

  2020cites this paper
• Myocardial Energy Metabolism in Non-ischemic Cardiomyopathy

  2020cites this paper
• APPL1 knockdown blocks adipogenic differentiation and promotes adipocyte lipolysis.

  2020cites this paper
• The tyrosine kinase inhibitor crizotinib influences blood glucose and mRNA expression of GLUT4 and PPARs in the heart of rats with experimental diabetes.

  2020cites this paper
• Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review

  2020cites this paper
• Role of Mitochondrial Quality Surveillance in Myocardial Infarction: From Bench to Bedside.

  2020cites this paper
• Analysis of fibroblasts from patients with cblC and cblG genetic defects of cobalamin metabolism reveals global dysregulation of alternative splicing.

  2020cites this paper
• Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients.

  2020cites this paper
• Metabolic impairment in response to early induction of C/EBPβ leads to compromised cardiac function during pathological hypertrophy.

  2020cites this paper
• The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.

  2020cites this paper
• Role of ceramides in the pathogenesis of diabetes mellitus and its complications.

  2020cites this paper
• Revisiting PPARγ as a new friend of GPR120 in the treatment of metabolic disorders

  2020cites this paper
• Arrhythmogenic cardiomyopathy: pathogenesis, pro-arrhythmic remodelling, and novel approaches for risk stratification and therapy

  2020cites this paper
• Novel Approaches for Omega-3 Fatty Acid Therapeutics: Chronic Versus Acute Administration to Protect Heart, Brain, and Spinal Cord.

  2020cites this paper
• Peroxisome Proliferator-Activated Receptors and Caloric Restriction—Common Pathways Affecting Metabolism, Health, and Longevity

  2020cites this paper
• Insights into the prognosis of lipidomic dysregulation for death risk in patients with coronary artery disease

  2020cites this paper
• Cardiac overexpression of perilipin 2 induces atrial steatosis, connexin 43 remodeling, and atrial fibrillation in aged mice.

  2019cites this paper
• Dietary Saturated Fat Promotes Arrhythmia by Activating NOX2 (NADPH Oxidase 2).

  2019cites this paper
• Dual PPAR α / γ activation inhibits SIRT1-PGC1 α axis and causes cardiac dysfunction

  2019cites this paper
• GCN2 deficiency ameliorates cardiac dysfunction in diabetic mice by reducing lipotoxicity and oxidative stress

  2019cites this paper
• Dual peroxisome-proliferator-activated-receptor-α/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction.

  2019influential citation